The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Kathleen N Moore - One of the best experts on this subject based on the ideXlab platform.

  • effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in Gynecologic oncology procedures a phase iii single institution prospective randomized trial
    Gynecologic Oncology, 2017
    Co-Authors: E D Thomas, Elizabeth K Nugent, Matthew C Macallister, Katherine M Moxley, Lisa M Landrum, Joan L Walker, D S Mcmeekin, Robert S Mannel, Gerald Mcgwin, Kathleen N Moore
    Abstract:

    Abstract Objectives Surgery is a cornerstone for patients with Gynecologic malignancies. Surgical site infections (SSI) remain a source of post-operative morbidity. Consequences range from escalated costs, delay in adjuvant therapy, and increased morbidity. Our primary objective was to evaluate the effectiveness of a cyanoacrylate microbial sealant (CMS) to reduce post-operative SSI following laparotomy for suspected Gynecologic malignancy. Methods Patients were randomized using a 1:1 allocation to receive either standard skin preparation or standard preparation with CMS and stratified by BMI. Patients were followed for 6weeks for SSI. Demographic data was collected through the EMR. Associations between SSI, use of CMS, and clinicopathologic factors were explored using descriptive statistics, chi-square and multivariate analysis. Results 300 patients underwent randomization. Median age of the cohort was 58. Arms were matched and there was no difference in rate of medical comorbidities. Mean BMI was 38.8kg/m 2 in patients randomized to BMI≥30 and 26.3kg/m 2 randomized to BMI p =0.18). Multivariate model demonstrated that BMI≥30 ( p p =0.010), transfusion in the OR ( p p =0.0005) were associated with post-operative SSI. Conclusions Patients presenting to a Gynecologic Oncologist for surgery frequently present with multiple risk factors for SSI and laparotomy is complicated by surgical-site complications in up to 30% of cases. The addition of CMS alone does not appear to reduce risk of overall SSI. Additional risk-reducing strategies including use of antimicrobial agents and optimization of modifiable risk factors prior to surgery should be explored as pathways for reducing this significant post-operative morbidity.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Gynecologic Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are non-inferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality. Recommendations All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and pelvis, and chest imaging (CT preferred). Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to Additional information is available at www.asco.org/NACT-ovarian-guideline and www.asco.org/guidelineswiki.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Gynecologic Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are non-inferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality. Recommendations All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and pelvis, and chest imaging (CT preferred). Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to Additional information is available at www.asco.org/NACT-ovarian-guideline and www.asco.org/guidelineswiki.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Journal of Clinical Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    PurposeTo provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.MethodsThe Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature.ResultsFour phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.RecommendationsAll women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and ...

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Journal of Clinical Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    PurposeTo provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.MethodsThe Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature.ResultsFour phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.RecommendationsAll women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and ...

Annekathryn Goodman - One of the best experts on this subject based on the ideXlab platform.

  • Gynecologic Oncologist as surgical consultant intraoperative consultations during general Gynecologic surgery as an important focus of Gynecologic oncology training
    Gynecologic Oncology, 2015
    Co-Authors: Emeline M. Aviki, Rachel M. Clark, Tracilyn Hall, Lori R. Berkowitz, David M. Boruta, Whitfield B. Growdon, John O. Schorge, Alejandro J Rauhhain, Annekathryn Goodman
    Abstract:

    OBJECTIVE: The aim of this study is to explore the previously unexamined role of the Gynecologic Oncologist as an intraoperative consultant during general Gynecologic surgery. METHODS: Demographic and clinical data were collected on 98 major Gynecologic surgeries that included both a general Gynecologist and a Gynecologic Oncologist between October 2010 and August 2014. Data were analyzed using XLSTAT-Prov2014.2.02. RESULTS: Of 794 major Gynecologic surgeries, 98 (12.3%) cases that involved an intraoperative consultation were identified. There were 36 (37%) planned consults and 62 (63%) unplanned consults. Significantly more planned consults were during laparoscopy (100% v 58%; p<0.01) and significantly more unplanned consults were during laparotomy (42% v 0%; p<0.01). The majority of planned consults were for surgical training (86%) and the most common reasons for unplanned consults were adhesions (40%), bowel injury (19%), inability to identify ureter (19%), and cancer (11%). The most common interventions performed during unplanned consults were identification of anatomy (55%), lysis of adhesions (42%), and retroperitoneal dissection (27%). Average surgeon years in practice were significantly lower for unplanned consults (9 v 15; p<0.01). A total of 25 major adverse events occurred in 15 cases with the majority occurring in cases with unplanned consults (23% v 3%; p<0.01). After controlling for laparotomy, unplanned consultation was not significantly associated with major events (OR=6.67, 95%CI 0.69-64.39; p=0.10). CONCLUSIONS: Gynecologic Oncologists play a pivotal role in the support of generalist colleagues during pelvic surgery. In this series, Gynecologic Oncologists were consulted frequently for complex major benign surgeries. It is important to incorporate the skills required of an intraoperative consultant into Gynecologic Oncology fellowship training.

  • Gynecologic Oncologist as surgical consultant: Intraoperative consultations during general Gynecologic surgery as an important focus of Gynecologic oncology training
    Gynecologic Oncology, 2015
    Co-Authors: Emeline M. Aviki, J. Alejandro Rauh-hain, Rachel M. Clark, Tracilyn Hall, Lori R. Berkowitz, David M. Boruta, Whitfield B. Growdon, John O. Schorge, Annekathryn Goodman
    Abstract:

    Abstract Objective The aim of this study is to explore the previously unexamined role of the Gynecologic Oncologist as an intraoperative consultant during general Gynecologic surgery. Methods Demographic and clinical data were collected on 98 major Gynecologic surgeries that included both a general Gynecologist and a Gynecologic Oncologist between October 2010 and August 2014. Data were analyzed using XLSTAT-Prov2014.2.02. Results Of 794 major Gynecologic surgeries, 98 (12.3%) cases that involved an intraoperative consultation were identified. There were 36 (37%) planned consults and 62 (63%) unplanned consults. Significantly more planned consults were during laparoscopy (100% v 58%; p p p p p =0.10). Conclusions Gynecologic Oncologists play a pivotal role in the support of generalist colleagues during pelvic surgery. In this series, Gynecologic Oncologists were consulted frequently for complex major benign surgeries. It is important to incorporate the skills required of an intraoperative consultant into Gynecologic Oncology fellowship training.

Don S Dizon - One of the best experts on this subject based on the ideXlab platform.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Gynecologic Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are non-inferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality. Recommendations All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and pelvis, and chest imaging (CT preferred). Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to Additional information is available at www.asco.org/NACT-ovarian-guideline and www.asco.org/guidelineswiki.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Gynecologic Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are non-inferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality. Recommendations All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and pelvis, and chest imaging (CT preferred). Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to Additional information is available at www.asco.org/NACT-ovarian-guideline and www.asco.org/guidelineswiki.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Journal of Clinical Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    PurposeTo provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.MethodsThe Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature.ResultsFour phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.RecommendationsAll women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and ...

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Journal of Clinical Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    PurposeTo provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.MethodsThe Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature.ResultsFour phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.RecommendationsAll women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and ...

  • sex intimacy and the Gynecologic Oncologist survey results of the new england association of Gynecologic Oncologists neago
    Journal of Psychosocial Oncology, 2007
    Co-Authors: Doreen L Wiggins, C O Granai, Roxanne Wood, Don S Dizon
    Abstract:

    Sexuality is an important aspect of life and is often affected in patients diagnosed with cancer. For women, estimates of sexual dysfunction range from 40 to 100%. In light of these statistics, we were interested in determining the comfort level and practice of specialists in Gynecologic oncology as it relates to taking a sexual history and addressing related concerns by conducting a survey of the New England Association of Gynecologic Oncologists (NEAGO). Our results show that although nearly all respondents felt comfortable addressing sexual problems in their patients, less than half took a sexual history in new patients and 80% did not feel there was sufficient time to devote to exploring sexual issues. The results of our survey suggest that aspects of sexual dysfunction in women with Gynecologic cancer may be neglected by Gynecologic oncology providers. This encourages cancer programs to develop formal resources for women with questions regarding sexuality following a diagnosis of cancer.

Emeline M. Aviki - One of the best experts on this subject based on the ideXlab platform.

  • Gynecologic Oncologist as surgical consultant intraoperative consultations during general Gynecologic surgery as an important focus of Gynecologic oncology training
    Gynecologic Oncology, 2015
    Co-Authors: Emeline M. Aviki, Rachel M. Clark, Tracilyn Hall, Lori R. Berkowitz, David M. Boruta, Whitfield B. Growdon, John O. Schorge, Alejandro J Rauhhain, Annekathryn Goodman
    Abstract:

    OBJECTIVE: The aim of this study is to explore the previously unexamined role of the Gynecologic Oncologist as an intraoperative consultant during general Gynecologic surgery. METHODS: Demographic and clinical data were collected on 98 major Gynecologic surgeries that included both a general Gynecologist and a Gynecologic Oncologist between October 2010 and August 2014. Data were analyzed using XLSTAT-Prov2014.2.02. RESULTS: Of 794 major Gynecologic surgeries, 98 (12.3%) cases that involved an intraoperative consultation were identified. There were 36 (37%) planned consults and 62 (63%) unplanned consults. Significantly more planned consults were during laparoscopy (100% v 58%; p<0.01) and significantly more unplanned consults were during laparotomy (42% v 0%; p<0.01). The majority of planned consults were for surgical training (86%) and the most common reasons for unplanned consults were adhesions (40%), bowel injury (19%), inability to identify ureter (19%), and cancer (11%). The most common interventions performed during unplanned consults were identification of anatomy (55%), lysis of adhesions (42%), and retroperitoneal dissection (27%). Average surgeon years in practice were significantly lower for unplanned consults (9 v 15; p<0.01). A total of 25 major adverse events occurred in 15 cases with the majority occurring in cases with unplanned consults (23% v 3%; p<0.01). After controlling for laparotomy, unplanned consultation was not significantly associated with major events (OR=6.67, 95%CI 0.69-64.39; p=0.10). CONCLUSIONS: Gynecologic Oncologists play a pivotal role in the support of generalist colleagues during pelvic surgery. In this series, Gynecologic Oncologists were consulted frequently for complex major benign surgeries. It is important to incorporate the skills required of an intraoperative consultant into Gynecologic Oncology fellowship training.

  • Gynecologic Oncologist as surgical consultant: Intraoperative consultations during general Gynecologic surgery as an important focus of Gynecologic oncology training
    Gynecologic Oncology, 2015
    Co-Authors: Emeline M. Aviki, J. Alejandro Rauh-hain, Rachel M. Clark, Tracilyn Hall, Lori R. Berkowitz, David M. Boruta, Whitfield B. Growdon, John O. Schorge, Annekathryn Goodman
    Abstract:

    Abstract Objective The aim of this study is to explore the previously unexamined role of the Gynecologic Oncologist as an intraoperative consultant during general Gynecologic surgery. Methods Demographic and clinical data were collected on 98 major Gynecologic surgeries that included both a general Gynecologist and a Gynecologic Oncologist between October 2010 and August 2014. Data were analyzed using XLSTAT-Prov2014.2.02. Results Of 794 major Gynecologic surgeries, 98 (12.3%) cases that involved an intraoperative consultation were identified. There were 36 (37%) planned consults and 62 (63%) unplanned consults. Significantly more planned consults were during laparoscopy (100% v 58%; p p p p p =0.10). Conclusions Gynecologic Oncologists play a pivotal role in the support of generalist colleagues during pelvic surgery. In this series, Gynecologic Oncologists were consulted frequently for complex major benign surgeries. It is important to incorporate the skills required of an intraoperative consultant into Gynecologic Oncology fellowship training.

Alexi A Wright - One of the best experts on this subject based on the ideXlab platform.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Gynecologic Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are non-inferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality. Recommendations All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and pelvis, and chest imaging (CT preferred). Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to Additional information is available at www.asco.org/NACT-ovarian-guideline and www.asco.org/guidelineswiki.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Gynecologic Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are non-inferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality. Recommendations All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and pelvis, and chest imaging (CT preferred). Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to Additional information is available at www.asco.org/NACT-ovarian-guideline and www.asco.org/guidelineswiki.

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Journal of Clinical Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    PurposeTo provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.MethodsThe Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature.ResultsFour phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.RecommendationsAll women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and ...

  • neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer society of Gynecologic oncology and american society of clinical oncology clinical practice guideline
    Journal of Clinical Oncology, 2016
    Co-Authors: Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore
    Abstract:

    PurposeTo provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.MethodsThe Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature.ResultsFour phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.RecommendationsAll women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a Gynecologic Oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and ...